Crossmark

Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice – results from the ElderTac study

Crossref DOI link: https://doi.org/10.1186/s12885-018-4208-x

Published Online: 2018-03-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Brueckl, Wolfgang M.

Achenbach, H. Jost

Ficker, Joachim H.

Schuette, Wolfgang
Funding

Funding for this research was provided by:

Roche Pharma AG (Not applicable)
License Information

Text and Data Mining valid from 2018-03-27
More Information

Article History

Received: 3 November 2017

Accepted: 9 March 2018

First Online: 27 March 2018

Ethics approval and consent to participate

: All participating patients provided written informed consent. The study was approved by the ethics committee of the Friedrich-Alexander-Universitaet Erlangen-Nuernberg (no. 4441).

: Not applicable.

: WMB received lecture and consultancy fees from Astra Zeneca, Boehringer Ingelheim, BMS, Lilly, MSD and Roche Pharma. JHF received lecture and consultancy fees from AstraZeneca, Boehringer Ingelheim, Lilly, Novartis, Pfizer, and Roche Pharma. WS declares receiving payments for lectures and consultancy from Roche Pharma. HJA received lecture and consultancy fees, as well as travel support from Bristol-Myers-Squibb, Boehringer Ingelheim, Grifols, Insmed, Lilly, Novartis, PneumRx, and Roche Pharma.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below